We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 243

Trump’s 2-for-1 Executive Order, its Impact on FDA, and the Significance of “Significant”
  • Arent Fox LLP
  • USA
  • February 10 2017

On the heels of a January 20, 2017 memorandum freezing the release of any new or pending regulations until they have been reviewed and approved by

Linda T. Coberly
  • Winston & Strawn LLP

Robin Shea
  • Constangy Brooks Smith & Prophete LLP

Jennifer A. Beckage
  • Phillips Lytle LLP

Chelsea Deppert
  • Fisher Phillips

Mark L. Stember
  • Kilpatrick Townsend & Stockton LLP

George Qi
  • Greenberg Traurig LLP

Stewart A. Baker
  • Steptoe & Johnson LLP

Sally Albertazzie
  • Steptoe & Johnson LLP

Dawn (Dan) Zhang
  • Greenberg Traurig LLP